Literature DB >> 21284707

Improving the quality of drug research or simply increasing its cost? An evidence-based study of the cost for data monitoring in clinical trials.

Esther Pronker1, Bart F Geerts, Adam Cohen, Herman Pieterse.   

Abstract

AIM: Procedures for verification of data from clinical studies are intended to maintain reliability for clinical trial results. Guidelines or legislations relating to clinical data management are of limited value and no study has yet demonstrated its effectiveness.
METHOD: Sponsor queries and dual entry procedures from one CRO on three different phase I trials are analysed on content, impact and cost. RESULT: In this study, sponsor queries and dual entry procedures proved time and cost inefficient in detecting data discrepancies.
CONCLUSION: We advocate a more evidence-based approach for enhancing data integrity throughout the process of clinical data management.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Mesh:

Year:  2011        PMID: 21284707      PMCID: PMC3045557          DOI: 10.1111/j.1365-2125.2010.03839.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  The continuing evolution of the drug discovery process in the pharmaceutical industry.

Authors:  E Ratti; D Trist
Journal:  Farmaco       Date:  2001 Jan-Feb

2.  Clinical trials bureaucracy: unintended consequences of well-intentioned policy.

Authors:  Robert M Califf
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

3.  Commercializing clinical trials--risks and benefits of the CRO boom.

Authors:  Miriam Shuchman
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

4.  2007 FDA drug approvals: a year of flux.

Authors:  Bethan Hughes
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

  4 in total
  10 in total

Review 1.  The impact of clinical trial monitoring approaches on data integrity and cost--a review of current literature.

Authors:  Rasmus Olsen; Asger Reinstrup Bihlet; Faidra Kalakou; Jeppe Ragnar Andersen
Journal:  Eur J Clin Pharmacol       Date:  2016-01-04       Impact factor: 2.953

2.  Clinical Monitoring in a Federally Funded Environment: Evolution and Opportunities in the Cardiovascular Cell Therapy Research Network.

Authors:  Sibi R Mathew; Kristen D Lucas; Shelly L Sayre; Judy Bettencourt; Tina Collins; Dana Leach; Rachel E Olson; Doris A Taylor; Lemuel Moyé
Journal:  Monitor (Assoc Clin Pharmacol)       Date:  2014-02

3.  Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials.

Authors:  Jeppe Ragnar Andersen; Inger Byrjalsen; Asger Bihlet; Faidra Kalakou; Hans Christian Hoeck; Gitte Hansen; Henrik Bo Hansen; Morten Asser Karsdal; Bente Juel Riis
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

4.  INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy.

Authors:  Katherine Huppler Hullsiek; Jonathan M Kagan; Nicole Engen; Jesper Grarup; Fleur Hudson; Eileen T Denning; Catherine Carey; David Courtney-Rodgers; Elizabeth B Finley; Per O Jansson; Mary T Pearson; Dwight E Peavy; Waldo H Belloso
Journal:  Ther Innov Regul Sci       Date:  2015-03-01       Impact factor: 1.778

5.  Industrialized research in the BJCP: a neo-Luddite view.

Authors:  Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

6.  A randomized evaluation of on-site monitoring nested in a multinational randomized trial.

Authors:  Nicole Wyman Engen; Kathy Huppler Hullsiek; Waldo H Belloso; Elizabeth Finley; Fleur Hudson; Eileen Denning; Catherine Carey; Mary Pearson; Jonathan Kagan
Journal:  Clin Trials       Date:  2019-10-24       Impact factor: 2.486

7.  Impact of a targeted monitoring on data-quality and data-management workload of randomized controlled trials: A prospective comparative study.

Authors:  Claire Fougerou-Leurent; Bruno Laviolle; Christelle Tual; Valérie Visseiche; Aurélie Veislinger; Hélène Danjou; Amélie Martin; Valérie Turmel; Alain Renault; Eric Bellissant
Journal:  Br J Clin Pharmacol       Date:  2019-12-14       Impact factor: 4.335

8.  Good Clinical Trials by removing defensive interpretation of Good Clinical Practice guidelines.

Authors:  Jonas M den Heijer; Jules A A C Heuberger; Hemme Hijma; Annelieke C Kruithof; Jeroen van Smeden; Geert Jan Groeneveld; Jacobus Burggraaf; Adam Cohen
Journal:  Br J Clin Pharmacol       Date:  2021-05-03       Impact factor: 3.716

9.  Generating evidence on a risk-based monitoring approach in the academic setting - lessons learned.

Authors:  Belinda von Niederhäusern; Annette Orleth; Sabine Schädelin; Nawal Rawi; Martin Velkopolszky; Claudia Becherer; Pascal Benkert; Priya Satalkar; Matthias Briel; Christiane Pauli-Magnus
Journal:  BMC Med Res Methodol       Date:  2017-02-14       Impact factor: 4.615

Review 10.  Central statistical monitoring of investigator-led clinical trials in oncology.

Authors:  Marc Buyse; Laura Trotta; Everardo D Saad; Junichi Sakamoto
Journal:  Int J Clin Oncol       Date:  2020-06-23       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.